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PENGHASILAN KAEDAH-KAEDAH UNTUK MENGUKUR KUALITI 
PRESKRIPSI DAN KOMPLIAN TERHADAP PENGUBATAN DALAM 
PESAKIT DARAH TINGGI DEW ASA 
ABSTRAK 
Objektiftesis ini ialah untuk menghasil dan mengesahkan kesahihan kaedah-kaedah baru 
. 
untuk pengukuran kualiti preskripsi, komplian terhadap pengubatan, dan faktor-faktor 
psikososial yang mempengaruhi ketidak komplian pesakit terhadap pengubatan. Kaedah 
ini akan digunakan sebagai pengukur yang berkualiti dari perspektif pegawai perubatan, 
pegawai farmasi dan pesakit. 
Indeks Preskripsi Berkualiti (PQI) telah dihasilkan berdasarkan hasil tiga tinjauan 
berasingan dan kajian pilot telah dijalankan dalam 120 pesakit kronik dan 240 pesakit 
darah tinggi. Soal-Selidik Komplian Terhadap Pengubatan (MCQ), Soal-Selidik 
Kepuasan Pesakit Dalam Penjagaan Kesihatan (PSHC), dan Soal-Selidik Psikososial 
(PQ) telah dihasilkan dan diukur kesahihannya dalam dua kajian pilot 60 pesakit darah 
tinggi yang berasingan. Seterusnya, kajian kohort telah dijalankan selama 6 bulan pada 
pesakit darah tinggi. Preskripsi ubat telah dinilai secara retrospektif dan soal-selidik diisi 
sendiri oleh pesakit. Hasil kajian telah dianalisa menggunakan SPSS versi 12.0.1. 
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lndeks Preskripsi Berkualiti mempamerkan Cronbach 's alpha bernilai 0.60 dan julat 
intra-rater dan inter-rater ialah dari 0.28 hingga 0.97 (purata: 0.76) dan 0.22 hingga 0.82 
(purata: 0.52) secara berturut. Nilai Cronbach 's alpha untuk Soal-Selidik Komplian 
Terhadap Pengubatan ialah 0.67 dan 0.84 dengan nilai test-retest dari 0.78 hingga 0.93. 
Untuk Soal-~elidik Kepuasan Pesakit Dalam Penjagaan Kesihatan, nilai Cronbach 's 
alpha ialah dari 0.76 hingga 0.91 dan test-retest dari 0.54 hingga 0.70. Nilai Cronbach 's 
alpha untuk Soal-Selidik Psikososial ialah dari 0.42 hingga 0.87 dan test-retest dari 0.53 
hingga 0.77. 
Seramai 184 pesakit telah menyempurnakan kajian dengan tujuh pesakit tidak dapat 
dikesan semasa lawatan susulan. Pendidikan tertiari (OR=0.11; 95% CI:0.03 to 0.43; 
p=0.001), bilangan ubat (OR=l.96; 95% CI:l.46 to 2.64; p<O.OOI), tempoh penyakit 
darah tinggi (OR=l.Ol; 95% CI:l.OO to 1.01; p=0.009), dan gaya hidup pesakit 
(OR=0.96; 95% CI:0.93 to 0.99; p=0.004) telah dikenalpasti sebagai faktor-faktor 
penting dan bebas yang mempengaruhi kualiti preskripsi. 
Pendidikan tertiari pesakit (OR=0.22; 95% CI:0.06 to 0.86; p=0.029), kepuasan pesakit 
dalam penjagaan kesihatan secara keseluruhan (OR=0.95; 95% CI:0.91 to 0.98;p=0.006), 
halangan pengubatan (regim yang kompleks, kos dan keberkesanan) (OR=0.92; 95% 
CI:0.86 to 0.97; p=0.006), dan halangan logistik dan kenderaan (OR=1.03; 95% CI: 1.01 
to 1.05; p=0.017) telah dikenalpasti sebagai faktor-faktor bebas dan penting yang 
mempengaruhi ketidak komplian terhadap pengubatan. 
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Sebagai kesimp.idan, tesis ini telah menghasilkan empat kaedah baru yang sahih dengan 
ciri-ciri psikometrik yang sederhana dan baik untuk digunakan dalam penjagaan pesakit 
dan juga kajian klinikal atau epidemiologi. Faktor-faktor yang berkaitan dengan kualiti 
preskripsi yang baik ialah pendidikan yang lebih tinggi, bilangan ubat yang sedikit, 
tempoh penyakit darah tinggi yang lebih pendek dan gaya hidup yang lebih sihat. Faktor-
faktor psikososial yang mempengaruhi ketidak komplian pesakit terhadap pengubatan 
ialah pendidikan pesakit, kepuasan p~sakit, halangan pengubatan, dan halangan logistik 
dan kenderaan. Kajian selanjutnya dalam penyakit dan populasi yang berlainan sangat 
dicadangkan. 
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DEVELOPM.ENT OF TOOLS TO MEASURE PRESCRIPTION QUALITY AND 
MEDICATION COMPLIANCE IN ADULT HYPERTENSIVE PATIENTS 
ABSTRACT 
The objectives of this thesis were to develop and validate new tools to measure 
prescription 9uality, medication compliance, and psychosocial factors contributing to 
non-compliance. These tools are to be used as quality measurement from the perspectives 
of clinicians, pharmacists and patients. 
The Prescription Quality Index (PQI) was developed based on three separate surveys and 
piloted in 120 patients with chronic illnesses and 240 patients with hypertension. The 
Medication Compliance Questionnaire (MCQ), Patient Satisfaction with Health Care 
Questionnaire (PSHC) and Psychosocial Questionnaire (PQ) were developed and 
validated in two separate pilot studies of 60 hypertensive patients each. A cohort study 
was then conducted for six months in patients with hypertension. Prescriptions were rated 
retrospectively and questionnaires were self-administered by patients. Results were 
analyzed using SPSS version 12.0.1. 
The PQI displayed Cronbach's alpha of 0.60 and range of intra-rater and inter-rater 
reliability were 0.28 to 0.97 (average: 0.76) and 0.22 to 0.82 (average: 0.52) respectively. 
The Cronbach's alpha for the MCQ were 0.67 and 0.84 with test-retest values of 0.78 and 
0.93. For the PSHC, the Cronbach's alpha ranged from 0.76 to 0.91 and test-retest ranged 
from 0.54 to 0.70. The Cronbach's alpha for the PQ ranged from 0.42 to 0.87 with test-
retest value of0.53 to 0.77. 
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A total of 184. patients completed the study with seven patients lost to follow-up. 
Tertiary education (OR=O.ll; 95% CI:0.03 to 0.43; p=O.OOI), number of drugs 
(OR=l.96; 95% CI:l.46 to 2.64; p<O.OOI), duration of hypertension (OR=l.Ol; 95% 
CI:l.OO to 1.01; p=0.009), and patients' lifestyle (OR=0.96; 95% Cl:0.93 to 0.99; 
p=0.004) have been identified as significant and independent factors associated with 
prescription quality. 
Patients' tertiary education (OR=0.22; 95% CI:0.06 to 0.86; p=0.029), overall satisfaction 
with health care (OR=0.95; 95% CI:0.91 to 0.98; p=0.006), medication barrier (complex 
regime, cost, and effectiveness) (OR=0.92; 95% CI:0.86 to 0.97; p=0.006), and logistic 
and transportation barrier (OR=1.03; 95% CI:l.Ol to 1.05; p=0.017), were identified as 
independent and significant factors associated with medication non-compliance. 
In conclusion, this thesis has generated four new tools with moderate to good 
psychometric properties to be used in patient care and for clinical or epidemiological 
studies. Factors associated with good prescription quality were higher education, lesser 
number of drugs, shorter duration of hypertension and healthier lifestyle. Psychosocial 
predictors of medication non-compliance were patient education, patient satisfaction, 
medication barrier, and logistic and transportation barrier. Future studies in other disease 
states and populations are highly recommended. 
XXVIII 
CHAPTER 1. INTRODUCTION 
1.1 Introduction 
Quality is one of the most predominant performance indicators in the services that an 
organization provides to its customers. In health care, quality is provided by a complex 
blend of multidisciplinary, technological and human resources. The challenge lies in 
providing good quality health care to increasingly high expectations of the populations, 
while ensuring safety and affordable health costs to everyone. Maintaining and improving 
quality standards are central to professionalism in health care. 
Variations in health care quality are far greater than most people realise. Kerr, et al., 
(2004) studied how effectively care is delivered in 12 metropolitan areas in United States 
and found that improvement are needed in overall quality and dimensions of preventive, 
acute and chronic care in all these communities. In the community with the highest 
overall quality score, less than 60% of effective care was delivered on average. This 
result was consistent with the findings from another study by McGlynn, et al., (2003). 
Most of the quality theories are applicable to health care. Quality can be defined and 
measured (Katz & Green, 1997). In addition, quality is dynamic and develops from 
continual improvement. It involves a competitive edge and a primary source of cost 
reduction. However, cost-reductions do not usually lead to improved quality and usually 
do not produce long-term lower costs. Quality has to do with doing the "right" things 
right the first time and efforts should be focussed toward achieving zero defects or 
deficits. Furthermore, quality also relates to outcomes, preferably improved clinical 
outcomes and is the responsibility for all persons involved. Quality and cost are linked 
and improvement in quality may be the key to control expenses and generate incomes. 
However, the, process of quality improvement itself can be a drain if not controlled and/or 
if the organization is improving the wrong processes. Quality and performance are 
synonymous. 
The growing interest m the quality of health care, cost-effectiveness, and patients' 
outcomes has stimulated the acceptance of the concepts of rational and evidence-based 
practices. There has been much emphasis on the need to improve clinical effectiveness by 
promoting rational and evidence-based medicine. Health practitioners are increasingly 
being called upon to account for their own practices and required to identify, appraise and 
implement evidence relevant to their work. Research findings need to be critically 
appraised in the light of detailed knowledge of local circumstances and practices. 
With the explosion of information technology and scientific knowledge, health care 
practitioners might not be able to keep up with the sheer quantity of published articles. In 
addition, they might not have the skills to distinguish between rigorous and useful 
research, and poor and unreliable findings (Trindler, 200 I). Many clinical studies are 
methodologically weak, not based on the gold standard of well conducted randomised 
controlled trial designs, or inapplicable within clinical or practice situations (Shelton, et 
a/., 1997). Practitioners might use interventions which are ineffective or even harmful 
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(Hennessy, et a!., 2003). Furthermore, adoption of effective interventions might be 
limited or slowed. Therefore, rational and evidence-based practice approach offered a 
tailor-made solution to these problems. 
Despite the campaigns by professional bodies and government departments to promote 
rational and evidence-based practice, the rate of change is slow. It is the responsibility of 
all health care personnel to maintain rational and evidence-based practices in their fields 
' 
so as to improve quality in health care. Consequently, outcomes of quality health care 
such as prescription quality will also improve. 
1.2 Definition 
Quality in health care is difficult to define and so it is not surprising that many definitions 
and dimensions of quality exist (Katz & Green, 1997). Initially, definitions of quality in 
health care tended to focus on the technical aspects of quality. Donabedian' approach to 
quality relate to structure, process, and outcomes. The author suggested three different 
definitions of quality based upon the notion of the benefits versus the harm of care 
(Donabedian, 1982). The absolutist definition of quality considers the possibility of 
benefit and harm to health as valued by practitioner, with no intention for monetary cost. 
The individualized definition of quality takes into account the patients' expectations of 
benefit/harm and other undesired consequences (e.g. monetary cost to client). Finally the 
social definition includes the cost of care and the benefit/harm and distribution of health 
care as valued by the population in general. He sees the balance of these benefits and 
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harms as the essential care of quality. Wyszewianski, eta/., (1987) definition includes 
accuracy of diagnosis and the appropriateness and efficacy of treatment rendered. 
The National Association of Quality Assurance Professionals (1996) defines quality as 
levels of excellence produced and documented in the process of patient care, based on the 
best knowledge available and achievable at a particular facility. This practical definition 
recognises the dynamic nature of information and acknowledges the limits of our 
scientific and technical knowledge and achievements. Furthermore, it suggests the 
responsibility of professionals for using the best information available and striving to 
increase that knowledge. 
Definition of quality health care and its measures vary depending on whose perspective is 
being considered. From the providers' perspectives, quality of care is defined as the 
ability of available healthcare services to produce the greatest improvement that science 
can achieve. However, clients' perspectives of quality involve accessibility to care; 
interpersonal processes, such as communication, friendliness, explanations, and 
sensitivity to clients' needs, and outcomes. Degree of improvement in health status and 
satisfaction with health services are two ways to measure outcomes. While definitions are 
important to help people to understand the concept of quality, it is the integrations and 
applications of these quality concepts that are of prime importance in health care. 
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1.3 Rational and evidence-based practice 
The preoccupation with quality and rationality has dominated healthcare management 
during the last two decades. Rational prescribing improves health quality by improving 
several aspects of drug utilisation process, such as the prescribing process. It requires 
physicians to make an accurate diagnosis, understand the pathophysiology of the disease 
, 
or condition, know the pharmacology of the prescribed drugs, and consider the many 
other elements of appropriate medication use, and monitor patient outcomes (Hanlon, et 
al., 1992; Chaudhury & Tripathi, 1997). 
The Conference of Experts on the Rational Use of Drugs, convened by the World Health 
Organizations (WHO) in Nairobi in 1985 defined that rational use of drugs requires that 
appropriate drug be prescribed, available at the right time, at affordable price, dispensed 
correctly, taken at the right dose at the right intervals, and for the right length of time. 
The appropriate drug must be effective, and of acceptable quality and safety. (Santoso, 
1996; Chaudhury & Tripathi, 1997; WHO, 2002). The terms "rational" and "appropriate" 
use of drugs will be used interchangeably throughout this thesis. 
Decisions in health care management and clinical practice should also be based on 
evidence (Dranitsaris, 200 I; Peat, et a/., 2002; Leape, et a/., 2002). Evidence-based 
medicine is defined as the systematic application of the best available evidence to the 
evaluation of options and decisions in clinical practice, management and policy-making 
(Sultz & Young, 2001). It is an approach to decision making in which the clinician uses 
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the best evidence available, in consultation with the patient, to decide upon the best 
option which suits that patient (Sackett, et a!., 1996). 
Evidence-based approach relies on sound methodological studies such as randomised 
controlled tri~ls to make informed clinical decisions. Five steps in evidence-based 
decision making are: asking the right questions, finding the relevant evidence, appraising 
the evidence to select the best, decision making based on the evidence, and storing the 
evidence for future use (Gray, 2001). It is the responsibility of organisation management, 
medical, pharmacy, other health care practitioners and researches to keep up to date with 
the latest evidence in their fields and change their practices accordingly to maintain and 
improve quality in health care. 
To facilitate rational and evidence-based prescribing, evaluation of factors such as 
physicians and patient characteristics and the efficacy and cost of individual drugs are 
required. This will involve a more sophisticated integration of existing information 
sources and the adoption of uniform guidelines. Any successful attempt to correct 
inappropriate prescribing must bring together people with skills in drug database and 
drug information systems such as clinical pharmacists and pharmacologists. 
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1.4 Factors affecting quality in health care 
Several factors may affect quality in health care (Figure 1.1). Prescribers play major roles 
and responsibilities in the management of patients' health care. Pharmacists contribute to 
health care with their pharmaceutical care services. These include promoting rational and 
effective use of drugs, drug information and education, drug distribution system, drug 
therapy monitoring and patients counselling. Patients may also contribute to quality 
health care with their knowledge, attitudes, beliefs, expectations, and compliance 
behaviour. Health regulators and health administrators play important roles in training 
their entire health care staffs to change their old ways and providing new technology. 
Health administrators have access to their current system to find out where and when 
problems occur, and decide which area need to change. 
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1.5 Quality in prescribing medications 
Medication therapy can improve quality health care through cure or prevention of 
disease, reduction or elimination of symptoms or arresting or slowing of a disease 
process. Whe~ used appropriately, medication therapy is often more effective than other 
kinds of treatment. However, inappropriate use can compromise patient safety, deplete 
health care resources, morbidity, and mortality. 
Medications have to be appropriately prescribed and dispensed before patients can 
optimise their benefits. However, several studies have shown that prescribing practices 
are frequently inappropriate, illogical and even dangerous (Coste & Venot, 1999; 
Lagerlov, et a!., 2001; Ni, et a!., 2002). Medical uncertainty, perception, social 
background, belief, attitude and patients expectations may cause variability in prescribing 
practices. Prescription is one of the direct outcomes of drug prescribing. Consequently, 
inappropriate prescribing practice also resulted in poor in prescription quality. 
1.6 Effects of poor prescription quality in health care 
It has been estimated that more than 50% of 1.8 billion prescriptions were used 
incorrectly. Drug related problems, including adverse drug reactions, accounted for 
nearly 10% of all hospital admissions and up to 140,000 deaths annually in the United 
States. The complexity of drug protocols and subsequent miscalculations, necessity for 
speed of actions in emergency situations, marketing of multiple concentrations of drug 
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products and availability of highly concentrated drug products on nursing units appear to 
have contributed to fatal medication errors (Philips, eta/., 2001). 
Prescription errors may result from a single or multiple breakdowns in a system's 
continuum of diagnosing an ailment, planning a therapeutic regimen, prescribing and 
dispensing drugs and administering the drugs. Medication errors occur in 3-6.9% of 
inpatients with a rate reported to be between 3.23-16.9% for inpatient drug order. For 
outpatient prescriptions, 3.2% contain major error (Bond & Raehl, 2001). Fatal 
medication errors accounted for approximately 10% of medication errors and were most 
frequently the result of improper dosing of the intended drug and administration of an 
incorrect drug (Philips, eta/., 2001 ). Increased awareness and improved understanding of 
the nature of the errors will be useful in the design of error preventive initiatives. 
1.7 Hypertension 
Hypertension is a major risk factor for developing coronary heart disease, stroke and 
congestive heart failure. The primary goal in treating hypertension is to achieve optimal 
blood pressure (BP) levels, thereby reducing the risks of cardiovascular morbidity and 
mortality (Harvey & Woodward, 2001; Neutel, 2002). However, despite broad and 
expanding choices in anti-hypertensive treatments, less than one third of hypertensive 
adults have their BP under control in the United States (Mancia, et a/., 2003). In 
Malaysia, Lim & Morad, (2004) in a population based-study reported that the prevalence 
of hypertension among adults aged 30 years and above was 33%. Among the 
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hypertensives, 33% were aware of their hypertension, 23% were treated and only 6% had 
controlled BP. 
Asch, eta/., (2001) reported that out of234 women with average BP of 140/90 mm Hg or 
more, only ~% received recommended care. Most patients did not receive adequate 
initial history, physical examination, or laboratory tests. Only 37% of hypertensive 
women with persistent BP elevations of ~ore than 160/90 mm Hg had changes in therapy 
or lifestyle recommended. 
The benefits of optimum BP control have been demonstrated to reduce the risks of major 
cardiovascular events (Hansson, et a/., 1998). The Hypertension Optimal Treatment 
(HOT) trial divided patients into target groups of diastolic BP>90, 86-90, 81-85, and <80 
mm Hg. The Psychosocial General Well Being Index Scale was used to measure quality 
of life (QOL). The researchers found that there was a proportional improvement in QOL 
when BP was lowered particularly with cardiac symptoms and headache. The risk for 
stroke, coronary heart disease, and other major cardiovascular events were lowest in 
patients assigned the most intensive BP lowering strategy compared to those with less 
intensive BP lowering strategy. 
Hypertension is selected as an appropriate disease model for this study. The silent nature 
of hypertension often leads to poor compliance and consequently, treatment failure. 
Unlike other chronic diseases, the consequences of non-compliance in hypertension are 
relatively delayed. In addition, Bloom, (2001) suggested that hypertension is the disease 
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in which compliance and persistence have been best studied. Furthermore, hypertension 
has well defined and established prescribing guidelines worldwide and locally. 
1.7.1 Definition and classification 
Hypertension was defined as systolic BP 2: 140 mm Hg and/or diastolic BP 2: 90 mm Hg 
or use of antihypertensive medication (Malaysian clinical practice guidelines on the 
management of hypertension, 2002; Chobanian, et al., 2003). The term hypertension 
refers to persistent elevation of BP as recorded several times on different days. Isolated 
office ("white-coat") hypertension is a condition noted in patients whose BP is 
consistently elevated in the physician's clinic but normal at other times. Isolated systolic 
hypertension is defined as systolic BP of2: 140 mm Hg and diastolic BP of:S 90 mm Hg. 
The classification of hypertension is important for physicians must make treatment 
decisions based on the measured BP and the patients' associated risk factors. Table I 
classified BP for adults aged 18 years. Patients with pre-hypertension are at increased risk 
for progression to hypertension. 
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Table 1.1 Classification and management of blood pressure for adults* 
Initial Drug Therapy 
BP Classification SBP DBP Lifestyle 
mmHg mm Hg Modification Without 
Compelling 
Indication 
With Compelling 
Indications 
(See Table 1.2) 
Normal < 120 and< 80 Encourage No Drug(s) for 
Pre-hypertension 120-139 
Stage I Hypertension 140-159 
Stage II Hypertension ~ 160 
DBP Diastolic blood pressure. 
SBP Systolic blood pressure. 
or 80-89 
. 
or 90-99 
or~ 120 
* Treatment determined by highest BP category. 
Yes 
Yes 
Yes 
antihypertensive compelling 
drug indicated 
Thiazide-type 
diuretics for 
most. May 
consider ACEI 
or ARB orBB 
orCCB 
Two drug 
indications# 
Drug(s) for the 
compelling 
indications# 
Other 
antihypertensive 
drugs (diuretics, 
ACEI, ARB, BB, 
combination for CCB) as needed 
most§ 
(Usually 
thiazide-type 
diuretic and 
ACEI or ARB 
orBB or CCB) 
§ Initially combined therapy should be used cautiously in those at risk for orthostatic hypotension. 
# Treat patients with chronic kidney disease or diabetes to BP goal of< 130/80 mm Hg. 
Drug abbreviations: ACEI, angiotensin converting enzyme inhibitor 
ARB, Angiotensin receptor blocker 
CCB, Calcium channel blocker 
BB, Beta-blocker 
Adapted from The Seventh Report of the Joint National Committee (JNCVII) on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure, 2003. 
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1.7.2 Pathogenesis 
In essential hypertension, several pathophysiologic mechanisms are involved including 
sympathetic nervous system regulation, cell membrane defects, and vascular and 
hormonal fa~tors. Associated physiologic abnormalities and risk factors are 
environmental and lifestyle factors, genetic factors, renin secretion, sensitivity to salt, 
insulin resistance, and electrolyte abnormalities (Waeber, 2002). Secondary hypertension 
is associated with a specific organ defect (usually kidney) or a metabolic or endocrine 
abnormality. 
1.7.3 Diagnosis of hypertension 
Diagnosis of hypertension is based on average BP 2::. 140/90 mm Hg on three sets of 
readings at least a week apart. It is well established that elevated systolic BP is an 
important cardiovascular risk factor. In hypertensive patients with diabetes and renal 
impairments, the threshold of diagnosis is 130/80 mm Hg. In patients with borderline or 
variable office BP measurements, consider home ambulatory BP measurements, with 
135/85 mm Hg as the hypertension threshold (Chobanian, et al., 2003). 
Elevated BP is usually an accidental finding discovered during physical examination of 
asymptomatic patient in most patients with uncomplicated essential hypertension. Blood 
pressure should be measured correctly and four most common devices used for BP 
measurement are mercury column sphygmomanometer, aneroid sphygmomanometer, 
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electronic devices, and automated ambulatory BP devices. However, mercury column 
sphygmomanometer remains as the gold standard for BP measurement. 
1. 7.4 Management of hypertension 
The concept of optimum efficacy with lowest side effects provides the rationale for 
recent hypertension treatment guidelines. Ideally, the drug should be efficacious, free 
from side effects, able to prevent all the complications of hypertension, easy to use and 
affordable. Treatment should be individualised. However, the choice of drugs is 
determined by the presence of concomitant conditions as well as psychosocial and 
economic factors (Malaysian clinical practice guidelines on the management of 
hypertension, 2002; Chobanian, et al., 2003). 
Non-pharmacologic treatment should be advised for those with pre-hypertension stage 
(Table 1.1, 1.2). Lifestyle measures include weight reduction, stress reduction, smoking 
cessation, reduction or avoidance of alcohol consumption, reduction in salt intake, 
reduction in fat and cholesterol intake, and increased physical activity (Harvey & 
Woodward, 2001). Dietary intakes with fish oil, potassium, calcium, magnesium and 
fibre has limited or unproven efficacy (Malaysian clinical practice guidelines on the 
management of hypertension, 2002). 
For stage I hypertension, thiazide diuretics are recommended for most cases. A period of 
3 to 6 months of observation is recommended unless target organ involvement is already 
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evident. With monotherapy, a reduction of up to 10/5 mm Hg is expected and adequate 
BP is achieved in only 40-50% of patients (Neutel, 2002). Combination therapy with 
small doses of 2 types of antihypertensives and non-pharmacologic approaches should be 
sufficient to control blood pressure in the majority of patients not controlled with 
monotherapy .. 
Stage II hypertension usually requires a two-drug combination. Use of low dosage 
combination therapy may facilitate maximum efficacy, improve tolerability, improve 
compliance and reduce side effects (Neutel, 2002; Waeber, 2002). Interest in using fixed-
dose combination therapy is increasing, particularly for meeting the more stringent BP 
goals recommended for hypertensive patients with concurrent medical problems such as 
diabetes and renal disease. Advantages of combination therapy are: higher response 
rates, additive effects at lower doses, potential for the individual components to attenuate 
or cancel compensatory hemodynamic changes induced by single agent therapy, potential 
to attenuate or cancel adverse reactions induced by single agents (eg. angiotensin 
converting enzyme inhibitors (ACEI) and diuretic combinations and hypokalemia), and 
potential to provide beneficial effects on target organ damage through effects unrelated to 
antihypertensive action. Patient perceived benefits of combination therapy are greater 
convenience, lower cost, fewer side effects (Frishman, et al., 1994) and better compliance 
(Schroeder, eta/., 2004). 
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Table 1.2 Guideline basis for compelling indications for individual drug classes 
Compelling Recommended Drugs 
Indications* Diuretic BB ACEI ARB CCB AI do 
anta 
Heart failure * * * * 
Post-myocardial * * 
infarction 
High coronary disease * * * * 
risk 
Diabetes * * * * * 
Chronic kidney disease * * 
Recurrent stroke * * 
prevention 
* Compelling indications for antihypertensive drugs are based on benefits from outcome studies or 
existing clinical guidelines; the complelling indication is managed in parallel with the BP 
Drug abbreviations: ACEI, Angiotensin converting enzyme inhibitor 
ARB, Angiotensin receptor blocker 
CCB, Calcium channel blocker 
BB, Beta-blocker 
Aldo anta, Aldosterone antagonist 
* 
* 
Adapted from The Seventh Report of the Joint National Committee (JNCVII) on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure, 2003. 
17 
Many drugs are available for hypertension treatment {Table 1.2). For patients with 
essential hypertension without co-morbid conditions or target organ damage, any drugs 
from the following classes can be used: diuretics, ACEI, angiotensin II receptor blockers 
(ARB), b-blockers, peripheral a-blockers, and calcium channel blockers (CCB). After up 
to 6 weeks ~nd BP is still not controlled, dose may be increased, or susbtitute with 
another class of drug or a second drug may be added (Malaysian clinical practice 
guidelines on the management of hypertension, 2002). 
Thiazide-type diuretics have been the drug of choice for most hypertensive patients, 
either alone or in combination with other drugs (ACEI, ARB, b-blockers, CCB). Beta-
blockers may be preferred initial agents in patients with angina, hypertrophic 
cardiomyopathy, hyperdynamic circulation, heart failure, diabetes, postmyocardial 
infarction, hypertension associated with cyclosporin (especially labetalol), and vascular 
headaches. On the other hand, beta-blockade is relatively or absolutely contraindicated in 
patients with bradycardia, heart block, peripheral vascular disease, sick-sinus syndrome, 
or asthma/chronic obstructive pulmonary disease (COPD). 
Angiotensin converting enzyme inhibitors have proven benefit for the treatment of 
hypertension with congestive heart failure, left ventricular dysfunction secondary to 
myocardial infarction, renal disease, and diabetes mellitus with proteinuria. Calcium 
channel blockers may be useful in patients with coronary heart disease. Furthermore, 
CCBs do not have significant adverse metabolic effects or compromise diabetic control 
or aggravate diabetic complications. 
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Despite the various and expanding choices of antihypertensive drugs, adequate control of 
BP are still unsatisfactory (Mancia, eta!., 2003; Lim & Morad, 2004). There are multiple 
reasons that contribute to inadequate BP control. The most important ones include patient 
non-compliance, reluctance of physicians to titrate antihypertensive medications, 
difficulty in achieving BP control with monotherapy, and lower goals for BP control 
(Neutel, 2002). 
1.8 Background problems 
The dynamic changes in health care practice and high rate of medication error call for 
new approaches to address the multi-dimensional and complex natures of quality health 
care. In 1999, The Institute of Medicine (10M) examined available information about 
errors in medical care and concluded that 44,000-98,000 Americans died each year from 
medical mistakes. Medication errors represented the largest single cause of errors in the 
hospital setting, accounting for more than 7,000 deaths annually. The problems are so 
huge that medication errors could be within the top 10 causes of death in the United 
States (Leape, et a!., 2002). The mistakes in medical care raised a substantial public 
concern and growing professional awareness with health care quality. 
The complex nature of medication error and factors contributing to poor prescribing 
quality may vary from country to country and its degree may change over time. 
Furthermore, despite the availability of abundant quality measures in health care, none is 
19 
specifically designed to measure the quality of prescriptions in clinical practice especially 
in patients with chronic diseases. 
1.9 Why the study is needed 
Many studies ratse serious questions about the prescribing appropriateness and 
prescription quality. Maintaining the current processes is clearly inadequate and 
systematic approaches to evaluate possible solutions by measuring structure, process and 
outcomes of patient care are needed. Evaluation of specific health related factors of 
quality such as prescribing quality, patients' characteristics, and patients' related · 
outcomes such as compliance, patient satisfaction and QOL are certainly required. In 
addition, identification of factors contributing to these quality outcomes should be 
performed. 
One of the great limitations in measuring the quality of prescriptions is the lack of 
detection method that is sufficiently simple, sensitive and specific to allow systematic use 
in clinical setting. Several prescribing indicators are available, but they are not 
specifically designed to address the multiple problems associated with prescription 
quality. The lapses in quality which are a subset of a deficient therapeutics and 
prescribing process are not fully detected by the present quality indicators. A valid and 
reliable tool to decide whether a prescription is of quality is badly needed. 
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Clinicians, pharmacists and patients differ in their perspectives of quality health care 
(Law, eta/., 2003). To clinicians and pharmacists, quality health care refers to how well 
they treat patients. In many areas of practice, perspectives of clinicians and pharmacists 
are influenced by their objectives, training, evidence from their own experience, and 
'standard practices' in their teams or organizations. However, patients' perspectives of 
quality health care are based mainly on their health expectations and needs. It is 
important to include patient-based m(jasures in the assessments of outcomes in quality 
because patient's perspectives do not necessarily correlate with objective measures or 
providers' perspectives. 
A study to generate new tools to measure quality outcomes from the perspectives of 
clinicians, pharmacists and patients is needed. Such a study should develop a new index 
to measure prescription quality from the perspectives of clinicians and pharmacists. 
Although patients are capable of evaluating the services provided, they are less capable of 
evaluating whether appropriate treatments are given for their complaints. The tool should 
be valid, reliable, practical, useful, applicable to a broad variety of medications and 
clinical conditions, and will serve as a way of monitoring prescription quality in clinical 
practice. In addition, it will extend our knowledge on other information related to 
prescription quality. This will enable quality of prescriptions to be measured, analysed, 
monitored, and benefits of interventions can be examined for further improvements in 
patients care. 
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In this thesis, assessment of quality from the patients' perspectives will be performed 
using self-administered questionnaires to assess compliance, patient satisfaction and 
QOL. These measures are primary outcomes from the patients' perspectives. These 
patient-centred measures are aimed to assess individual's health state or health-related 
experience. Upderstanding patients' perspectives of quality and factors affecting these 
perspectives can help healthcare providers to identify problems, plan and target 
interventions, and plan preventive prowams to improve patient outcomes. 
1.10 Conceptual frameworks 
Donabedian conceptualization of structure, process, and outcome quality model was used 
as an approach in this study for index construction and development of patient 
satisfaction with Health Care Questionnaire. The Donabedian's quality model is selected 
for this study because it has a broad and long history of applicability. The concepts have 
been used, expanded, challenged, refined, and proven by the author himself, and by other 
researchers (Tasso, et a!., 2002; Gagnon & Grenier, 2004; Zanni, 2006). According to 
Donabedian, quality is a measure of organization effectiveness as assessed through 
quality indicators, and categorised as structure, process and outcome variables 
Donabedian, et al., 1982). These variables are causally linked, with good structure setting 
the condition for good process, which leads to good outcomes. 
Structure indicator is a quantitative measure that reflects the availability of resources. 
Structure represents the attributes of the care settings and should be monitored 
22 
periodically to .confirm that the capacity to provide quality care is present. However, 
structure is limited in its value of assessing quality of care because its measures are 
relatively stable and may not be sensitive or specific enough to monitor ongoing 
activities. 
Process is what is done in caring for patients. It is the content of care and measures what 
happens as care is sought, designed and provided directly to patients. Process may be 
technical such as diagnosing patient problems, prescribing medications, reviewing 
prescriptions, dispensing medications, providing information and patient monitoring or 
can be interpersonal such as empathy, friendliness, concern, and considerate. The process 
measures appeal to most researchers because they directly measures what the providers 
are doing. Changes in the process of care will influence the outcome. 
Finally, outcome is the effect ofthe care process on health and well-being of patients and 
populations. Outcome measures are of major interests to health care providers, policy 
makers, and patients because they are directly relevant to the goal of care to improve 
health status. The scope of outcomes has expanded far beyond the traditional measures of 
mortality and morbidity. In this thesis, outcomes will be measured from the providers' 
perspectives such as quality of prescriptions, and from the patients' perspectives such as, 
compliance, patient satisfaction and quality of life. 
The most complete quality assessment tool requires measuring all the three categories of 
variables. However, other factors such as simplicity, practicality, feasibility, manpower, 
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time limitation&~ and lack of sufficient resources should also be taken into consideration 
in developing quality measurement tools. 
1.11 Hypotheses 
The hypotheses for the studies are: 
1.11.1 Hypothesis of Study I 
I. Age and number of drugs significantly affect prescription quality in 
hypertension. 
1.11.2 Hypotheses of Study II 
I. Emotional states significantly affect compliance in hypertensive 
patients on pharmacotherapy. 
II. There is a significant correlation between quality of prescriptions and 
compliance. 
24 
